Tom Maniatis

Tom Maniatis is the founder of Kallyope, a company that focuses on the development of treatments for neurological diseases. Prior to their current position, Tom worked as a scientist at Regeneron Pharmaceuticals, Inc. from August 2016 to October 2017. Their responsibilities at Regeneron included characterizing monoclonal antibodies using functional assays for immuno oncology IO targets, characterizing bispecific antibodies using several in vitro cell-based assays, determining the mechanism of action of IO target molecules using in vitro functional cell-based assays, and designing and conducting multi color flow to immuno-phenotype TILs.

Before their time at Regeneron, Tom was an associate research scientist at Columbia University Medical Center from February 2011 to July 2016. Their research at Columbia University Medical Center focused on understanding the link between neuronal cell adhesion molecules and neuropsychiatric disorders. This research included characterizing protocadherin missense mutations identified in patients with neuropsychiatric disorder using human iPSC derived neurons and transgenic mice, investigating neuronal signaling pathways mediated by protocadherins to understand their role in brain wiring, and understanding of human genetic disease by CRISPR gene editing in stem cells to study the mutation in neuronal cell adhesion proteins.

Tom Maniatis has a Ph.D. in Cell/Cellular and Molecular Biology from Nanyang Technological University Singapore and a Bachelor's degree in Biology/Biological Sciences, General from the same school.